Mvasi
- Generic Name: bevacizumab-awwb solution for intravenous infusion
- Brand Name: Mvasi
- Drug Class: , Antineoplastics, VEGF Inhibitor
Mvasi (Bevacizumab-awwb Solution for Intravenous Infusion) side effects drug center
Mvasi Side Effects Center
What Is Mvasi?
Mvasi (bevacizumab-awwb) Solution is a vascular endothelial growth factor-specific angiogenesis inhibitor indicated for the treatment of metastatic colorectal cancer, with intravenous 5-fluorouracil–based chemotherapy for first- or second-line treatment; for metastatic colorectal cancer, with fluoropyrimidine-irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy for second-line treatment in patients who have progressed on a first-line bevacizumab product-containing regimen; for non-squamous non-small cell lung cancer, with carboplatin and paclitaxel for first line treatment of unresectable, locally advanced, recurrent or metastatic disease; for glioblastoma, as a single agent for adult patients with progressive disease following prior therapy; for metastatic renal cell carcinoma with interferon alfa; and for cervical cancer, in combination with paclitaxel and cisplatin or paclitaxel and topotecan in persistent, recurrent, or metastatic disease.
What Are Side Effects of Mvasi?
Common side effects Mvasi include:
- nosebleed,
- headache,
- high blood pressure (hypertension),
- runny nose,
- protein in the urine,
- taste alteration,
- dry skin,
- rectal bleeding,
- Site search
- Contact
- Location map
- For professionals
